profit from every $100 of sales.
$0$100
MannKind
$4.13-0.72% today
-18.5% in 1 year
1-year low $2.281-year high $6.21
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2022 to 2025.
0%20% a year
You pay $226.57 for every $1 of profit it makes in a year.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What MannKind sold, what it kept, and what it did with the cash.
Sales went from $99.8 million in 2022 to $349 million in 2025, with $5.86 million of profit last year.
SalesProfit
MannKind vs. similar companies
MannKind grows the fastest of these 5 and is the most expensive for its profits.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| MannKind | 226.6× · Very expensive | ||
 Vertex Pharmaceuticals | 34.5× · Expensive | ||
 Regeneron Pharmaceuticals | 21.9× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads MannKind's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 100 | 199 | 286 | 349 | |
| 42 | 136 | 209 | 261 | |
| -69 | 11 | 69 | 47 | |
| -56 | 19 | 76 | 52 | |
| -87 | -12 | 28 | 6 | |
| -0.34 | -0.04 | 0.10 | 0.02 | |
| 42.4% | 68.5% | 73.2% | 74.8% | |
| -69.1% | 5.3% | 24.1% | 13.3% | |
| -87.6% | -6.0% | 9.7% | 1.7% |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 295 | 475 | 394 | 792 |
| Cash | 70 | 238 | 46 | 75 |
| Total debt | 279 | 273 | 50 | 367 |
| Total liabilities | 546 | 721 | 473 | 843 |
| -251 | -246 | -79 | -51 | |
| 257 | 267 | 284 | 314 | |
| -174.9% | 43.5% | – | 9.8% | |
| 34.9% | 4.8% | -35.0% | -11.5% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -81 | 34 | 43 | 18 | |
| 8 | 42 | 10 | 5 | |
| -88 | -8 | 33 | 14 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 13 | 18 | 21 | 24 |
Valuation
- 226.6×
- 254.2×
- –
- -17.5×
- 3.8×
- 97.0×
- 31.5×
- 1.0%
- 0.4%
- 0.0%
Profitability
- 74.8%
- 13.3%
- 1.7%
- 7.9%
- 1.8%
- -92.9%
- 45.6%
- -3.2%
- 2.2%
- 20.1%
Growth
- +51.8%
- –
- −58.3%
- –
- +5.2%
Financial health
- 13.5×
- -7.38
- 58.7%
- 0.3×
- 1.87
- 1.50
- 0.48
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 41%of 946
Top 40%of 872
Bottom 2%of 565
Top 12%of 867
Bottom 49%of 986
What analysts expect
- Average price target
- $7.00
- Range
- $6.00 – $8.00
- 2 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 6, 2026 | -0.05 | -0.02 | −150.0% |
| Feb 26, 2026 | -0.05 | -0.01 | −400.0% |
| Nov 5, 2025 | 0.03 | 0.01 | +200.0% |
| Aug 6, 2025 | 0.00 | 0.04 | −94.6% |
| May 8, 2025 | 0.04 | 0.03 | +33.3% |
| Feb 26, 2025 | 0.03 | 0.03 | +0.0% |
| Nov 7, 2024 | 0.04 | 0.06 | −33.3% |
| Aug 7, 2024 | 0.05 | -0.03 | +249.9% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
26No pass
Benjamin Graham
24No pass
Philip Fisher
49No pass
Peter Lynch
71Pass
Joel Greenblatt
1No pass
Charlie Munger
31No pass
Terry Smith
43No pass
Questions about MannKind
Is MannKind a good stock to buy?
A business with weak numbers, priced as if everything goes right. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the MannKind AI analysis
What does MannKind do?
MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It is in Biotechnology.
Does MannKind pay a dividend?
No. MannKind does not pay a dividend at the moment.
Is MannKind stock halal?
Yes. MannKind passes our halal screen: its business is permitted and its debt is 27% of its market value, under the 30% limit. How we check
How has MannKind stock done over the past year?
Down 18.5% over the past twelve months, to $4.13. It traded between $2.28 and $6.21 and is 33.5% below its high.
Who are MannKind's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with MannKind's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.